ASBP vs XXII vs CRON vs CGC

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Analysts rate Cronos Group Inc. (CRON) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cronos Group Inc.

(CRON) delivered a total return of -66. 6%, compared to -100. 0% for 22nd Century Group, Inc. (XXII). Over 10 years, the gap is even starker: CRON returned +1458% versus XXII's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 98β versus Canopy Growth Corporation's 1. 90β — meaning CGC is approximately 93% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: 22nd Century Group, Inc. grew EPS 99. 9% year-over-year, compared to -100. 0% for Cronos Group Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cronos Group Inc.

(CRON) is the more profitable company, earning -4. 9% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps -4. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRON leads at -1. 5% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ASBP leads at 45. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CGC: 1180.

5% to $14. 47.

In this comparison, XXII (100.

0% yield) pays a dividend. ASBP, CRON, CGC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, CGC: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ASBP (Healthcare) and XXII (Consumer Defensive) and CRON (Healthcare) and CGC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ASBP is a small-cap quality compounder stock; XXII is a small-cap high-growth stock; CRON is a small-cap high-growth stock; CGC is a small-cap quality compounder stock. XXII pays a dividend while ASBP, CRON, CGC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.